Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma

Katrine Praetorius, Daniel P. Henriksen, Johannes M. Schmid, Pernille Printzlau, Lars Pedersen, Hanne Madsen, Ehm A. Andersson, Louise Klokker Madsen, Bo L. Chawes*

*Corresponding author for this work

Research output: Contribution to journalComment/debateResearchpeer-review

47 Downloads (Pure)

Abstract

This indirect comparison of dupilumab, mepolizumab and omalizumab for patients with severe type 2 asthma fulfilling start-up criteria for more than one drug shows no significant efficacy differences
Original languageEnglish
JournalERJ Open Research
Volume7
Issue number3
ISSN2312-0541
DOIs
Publication statusPublished - 1. Jul 2021

Fingerprint

Dive into the research topics of 'Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma'. Together they form a unique fingerprint.

Cite this